T M Tzschentke

Summary

Country: Germany

Publications

  1. ncbi request reprint Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction
    Thomas M Tzschentke
    Grunenthal GmbH, Biomedical Research, Department of Pharmacology, Postfach 500444, 52088 Aachen, Germany
    Psychopharmacology (Berl) 161:1-16. 2002
  2. ncbi request reprint Effects of venlafaxine and desipramine on heroin-induced conditioned place preference in the rat
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Germany
    Addict Biol 11:64-71. 2006
  3. ncbi request reprint (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Aachen, Germany
    J Pharmacol Exp Ther 323:265-76. 2007
  4. ncbi request reprint Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
    Thomas M Tzschentke
    Grunenthal GmbH, Preclinical Research and Development, Department of Pharmacology, Aachen, Germany
    Addict Biol 12:227-462. 2007
  5. ncbi request reprint Pharmacology and behavioral pharmacology of the mesocortical dopamine system
    T M Tzschentke
    Grunenthal GmbH, Research and Development, Department of Pharmacology, Postfach 500444, 52088, Aachen, Germany
    Prog Neurobiol 63:241-320. 2001
  6. ncbi request reprint Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol
    Thomas M Tzschentke
    Grunenthal GmbH, Research and Development, Department of Pharmacology, Postfach 500444, 52088 Aachen, Germany
    Neurosci Lett 329:25-8. 2002
  7. ncbi request reprint Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, 52099, Aachen, Germany
    Psychopharmacology (Berl) 172:58-67. 2004
  8. ncbi request reprint Glutamatergic mechanisms in addiction
    T M Tzschentke
    Grunenthal GmbH, R and D, Department of Pharmacology, Aachen, Germany
    Mol Psychiatry 8:373-82. 2003
  9. ncbi request reprint The medial prefrontal cortex as a part of the brain reward system
    T M Tzschentke
    Department of Pharmacology, Research and Development, Grunenthal GmbH, Aachen, Federal Republic of Germany
    Amino Acids 19:211-9. 2000
  10. pmc Synergistic interaction between the two mechanisms of action of tapentadol in analgesia
    W Schroder
    Global Preclinical Research and Development, Department of Pharmacology, Grunenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Germany
    J Pharmacol Exp Ther 337:312-20. 2011

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction
    Thomas M Tzschentke
    Grunenthal GmbH, Biomedical Research, Department of Pharmacology, Postfach 500444, 52088 Aachen, Germany
    Psychopharmacology (Berl) 161:1-16. 2002
    ..Recently, a new transdermal formulation of buprenorphine in slow-release matrix patches has been introduced (Transtec) for the treatment of intermediate to severe pain...
  2. ncbi request reprint Effects of venlafaxine and desipramine on heroin-induced conditioned place preference in the rat
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Germany
    Addict Biol 11:64-71. 2006
    ..Alternatively, the modulation of acquisition of heroin IVSA in the previous study may be related to mechanisms that cannot be modelled with the CPP paradigm...
  3. ncbi request reprint (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Aachen, Germany
    J Pharmacol Exp Ther 323:265-76. 2007
    ..It is suggested that the broad analgesic profile of tapentadol and its relative resistance to tolerance development may be due to a dual mode of action consisting of both MOR activation and NE reuptake inhibition...
  4. ncbi request reprint Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
    Thomas M Tzschentke
    Grunenthal GmbH, Preclinical Research and Development, Department of Pharmacology, Aachen, Germany
    Addict Biol 12:227-462. 2007
    ....
  5. ncbi request reprint Pharmacology and behavioral pharmacology of the mesocortical dopamine system
    T M Tzschentke
    Grunenthal GmbH, Research and Development, Department of Pharmacology, Postfach 500444, 52088, Aachen, Germany
    Prog Neurobiol 63:241-320. 2001
    ....
  6. ncbi request reprint Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol
    Thomas M Tzschentke
    Grunenthal GmbH, Research and Development, Department of Pharmacology, Postfach 500444, 52088 Aachen, Germany
    Neurosci Lett 329:25-8. 2002
    ..The low propensity to induce addiction may be related to the lack of changes in the brain circuitry mediating reward and motivation, as evidenced by the lack of sensitization...
  7. ncbi request reprint Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, 52099, Aachen, Germany
    Psychopharmacology (Berl) 172:58-67. 2004
    ..It is a potent micro -receptor partial agonist with a long duration of action. An inverted U-shaped dose-effect curve for buprenorphine conditioned place preference (CPP) has been shown previously...
  8. ncbi request reprint Glutamatergic mechanisms in addiction
    T M Tzschentke
    Grunenthal GmbH, R and D, Department of Pharmacology, Aachen, Germany
    Mol Psychiatry 8:373-82. 2003
    ..A better understanding of the underlying mechanisms might open new avenues to the treatment of addiction, in particular regarding relapse prevention...
  9. ncbi request reprint The medial prefrontal cortex as a part of the brain reward system
    T M Tzschentke
    Department of Pharmacology, Research and Development, Grunenthal GmbH, Aachen, Federal Republic of Germany
    Amino Acids 19:211-9. 2000
    ....
  10. pmc Synergistic interaction between the two mechanisms of action of tapentadol in analgesia
    W Schroder
    Global Preclinical Research and Development, Department of Pharmacology, Grunenthal GmbH, Zieglerstrasse 6, 52078 Aachen, Germany
    J Pharmacol Exp Ther 337:312-20. 2011
    ..This is probably the first demonstration of a synergistic interaction between the occupied receptors for a single compound with two mechanisms of action...
  11. doi request reprint Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats
    P Bloms-Funke
    Grunenthal GmbH, Global Preclinical Research and Development, 52099 Aachen, Germany
    Neurosci Lett 490:191-5. 2011
    ....
  12. doi request reprint In vitro and in vivo characterization of tapentadol metabolites
    R Terlinden
    Department of Pharmacokinetics, Global Preclinical Research and Development, Grunenthal GmbH, Aachen, Germany
    Methods Find Exp Clin Pharmacol 32:31-8. 2010
    ..Thus, it is highly unlikely that tapentadol forms metabolites that contribute in any relevant degree to its analgesic activity...
  13. ncbi request reprint Blockade of behavioral sensitization by MK-801: fact or artifact? A review of preclinical data
    T M Tzschentke
    Grunenthal GmbH, Research and Development, Aachen, Germany
    Psychopharmacology (Berl) 151:142-51. 2000
    ....
  14. ncbi request reprint Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction
    T M Tzschentke
    Grunenthal GmbH, Research and Development, Department of Pharmacology, Aachen, Germany
    Amino Acids 23:147-52. 2002
    ..Preclinical findings and the first clinical results are encouraging, and it may be that such subunit-selective compounds may have a sufficiently wide therapeutic window to be safe for human use...
  15. ncbi request reprint The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats
    Zofia Magalas
    Department of Pharmacology, Preclinical Research and Development, Grunenthal GmbH, 52099 Aachen, Germany
    Eur J Pharmacol 528:103-9. 2005
    ..Thus, daily treatment with an antidepressant attenuates the acquisition of heroin self-administration in a behaviourally specific manner, while having only marginal effects on maintenance of heroin self-administration...
  16. ncbi request reprint Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat
    Elizabeth L van der Kam
    Grunenthal GmbH, Preclinical Research and Development, Department of Pharmacology, Aachen, Germany
    Behav Pharmacol 18:717-24. 2007
    ..It is suggested that the differential effect of MPEP on IVSA of ketamine and heroin is related to the particular class of the self-administered drug or its relative reinforcing efficacy...